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One of the few issues uniting U.S. voters in the 2016 election was outrage over the high prices of medicines. From the quadrupling of 
EpiPen prices to $1,000-per-pill hepatitis C treatments, 
from six-digit pricing of cancer 
drugs to the 55-fold price increase 
on a 62-year-old toxoplasmosis 
drug, the scandals keep coming. 
In Europe, where government in-
volvement in price negotiations 
means that new drugs, diagnos-
tics, and vaccines (“medicines”) 
can cost less than half their U.S. 
prices, there is nevertheless seri-
ous concern that yearly price in-
creases will break health system 
budgets. Worldwide drug spend-
ing grew by about 9% in 2014 
and 2015, outpacing both overall 
health expenditures and econom-
ic growth.1
But what has recently been 
headline news in high-income 
countries has long been a concern 
everywhere else. Whether low- and 
middle-income countries (LMICs) 
are struggling to treat millions of 
people living with HIV or to im-
munize refugee children against 
pneumonia, unaffordable prices 
mean that many people simply 
go without. Meanwhile, despite 
billions of public and private dol-
lars invested in pharmaceutical re-
search and development, urgent 
needs for new antibiotics and 
tools for other public health pri-
orities go unmet. Unaffordable 
medicines and inadequate inno-
vation have become global issues. 
Like climate change, they require 
new public policies and interna-
tional cooperation.
Responding to concerns raised 
by patients and health advocates 
worldwide, in 2015 United Na-
tions (UN) Secretary General Ban 
Ki-Moon convened a High-Level 
Panel on Access to Medicines led 
by two former heads of state, Ruth 
Dreifuss of Switzerland and Festus 
Mogae of Botswana, together with 
13 international experts with wide-
ranging perspectives. Even before 
the report was published in Sep-
tember 2016 (www . unsgaccessmeds 
. org/ final-report), it had attracted 
an unusual degree of attention — 
both positive and negative — from 
governments, the pharmaceutical 
industry, and civil society. Some 
of the reaction, epitomized by the 
U.S. Chamber of Commerce state-
ment “condemn[ing the] U.N. re-
port attacking patents,”2 reflected 
a decades-old debate over the ap-
propriate relationship between in-
tellectual property monopolies and 
medicine prices. Yet the report 
does not generally go beyond pre-
existing international agreements 
on patents. Rather, the true source 
of consternation may be that it 
reframes the access-to-medicines 
challenge not only as involving 
prices in LMICs, but also as re-
quiring systemic changes to the 
prevailing research-and-develop-
ment business model for the sake 
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of all countries. The panel then 
advances some powerful ideas re-
garding such changes.
One of those ideas is trans-
parency. Reliable, thorough public 
information is not generally avail-
able on the safety, efficacy, prices, 
patent status, sources of invest-
ment, and costs of developing life-
saving medicines. Given its pro-
found implications for the public 
interest, the drug-development sys-
tem is shrouded in a dispropor-
tionate degree of secrecy. The panel 
recommended that governments 
mandate disclosure of information 
on various aspects of pharmaceu-
tical development, including re-
search-and-development costs. De-
pending on the information source 
and the methods used, estimates 
of the cost of developing a new 
drug vary by a factor of 40 or 
more — ranging from $92 mil-
lion to $4.2 billion.3 Transparen-
cy could introduce some measure 
of reason and evidence into heat-
ed pricing debates, which too of-
ten deteriorate into hyperbolic 
claims that any interference with 
free-market pricing would destroy 
innovation. A more granular un-
derstanding of research and de-
velopment could also shed light 
on the efficiency of the processes 
involved and spark debate about 
how society ought to appropri-
ately compensate investment, out-
comes, and risk and calibrate fi-
nancial rewards to the degree of 
therapeutic advance offered.
Transparency is also key to 
another powerful idea endorsed 
by the panel: ensuring public re-
turn on public investment in medi-
cine development. Drug develop-
ment is a public–private enterprise, 
with the public investing in basic 
research and early-stage discovery 
through taxpayer funding of aca-
demic and public laboratories and 
then purchasing the medicines 
that private firms develop through 
insurance policies or out-of-pocket 
expenditures. In areas in which 
the market fails to offer adequate 
incentives for innovation — such 
as neglected diseases, emerging 
infectious diseases, or antimicro-
bial resistance — public funding 
and priority setting play an even 
greater role, subsidizing all stag-
es of product development. For ex-
ample, the U.S. government’s Bio-
medical Advanced Research and 
Development Authority has fund-
ed private firms to develop medi-
cines for use in potential out-
breaks and has obtained approval 
from the Food and Drug Admin-
istration for 24 products since its 
founding in 2006. Transparency 
regarding public contributions to 
the research underlying a medi-
cine could provide a foundation 
for tempering excessive pricing, 
either in advance through condi-
tions imposed on public financ-
ing or after development through 
government regulation.
The report also calls for testing 
and implementing new business 
models of research and develop-
ment that would build affordabil-
ity into the product-development 
process by delinking research fi-
nancing from end-product prices. 
Some such models have already 
been proven to work in not-for-
profit drug-development efforts. 
For example, with $290 million 
from public funds and philan-
thropic contributions, the Drugs 
for Neglected Diseases Initiative 
(DNDi) put 26 candidate prod-
ucts into the development pipe-
line and brought 6 to market in 
10 years; because the research 
costs have already been covered, 
DNDi’s products can be sold for 
approximately the cost of produc-
tion.4 Though there are important 
differences between drug devel-
opment for neglected diseases and 
other therapeutic areas, this ex-
ample offers proof of principle 
regarding better ways to manage 
public and private investments to 
channel research and develop-
ment in the public interest.
Finally, the panel called for 
governments and companies to 
adhere to established agreements 
to protect access to medicines un-
der international trade rules. For 
example, governments have the 
authority to decide when a private 
patent right can be set aside in 
the interest of public health — a 
right that has been reaffirmed in 
every relevant UN political declara-
tion since 2001. Though the phar-
maceutical industry has criticized 
the report as an attack on patents, 
the panel in fact recommended 
only that preexisting agreements 
be enforced; it did not recommend 
additional patent f lexibilities be-
yond what has been agreed on 
for 15 years. Indeed, some panel 
members and civil-society orga-
nizations expressed disappoint-
ment that it did not call for a 
more dramatic overhaul of intel-
lectual-property treaties.
Among the report’s authors is 
the chief executive officer of 
GlaxoSmithKline (GSK), Andrew 
Witty, who has occasionally be-
come a thorn in his industry’s side 
by taking positions ahead of the 
curve. For example, he has called 
the $1 billion research-and-devel-
opment price tag a myth reflect-
ing inefficiencies rather than re-
quired costs; he expanded GSK’s 
policy of licensing generic versions 
of patented medicines in some 
LMICs beyond HIV to include can-
cer; and he has endorsed new 
research-and-development models 
to combat antimicrobial resistance 
and pathogens of pandemic po-
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tential. His peers may wish to 
reexamine some of the business 
models advanced in the report, 
which could continue rewarding 
innovation while satisfying grow-
ing public demands for affordabil-
ity and needs-driven innovation.
Given the charged politics of 
debates over access to medicines, 
I believe Secretary General Ban 
was courageous to convene this 
panel — though the report’s fate 
in the UN system is uncertain, 
given that there is a new secretary 
general, a new U.S. 
president, and a 
new director gen-
eral of the World 
Health Organization in 2017. Nev-
ertheless, the panel’s greatest im-
pact may be realized not through 
intergovernmental talks, but by 
stimulating public debate over 
ways of reforming the research-
and-development system to better 
serve the global public interest. 
The Netherlands’ trade and health 
ministers recently echoed three 
panel recommendations, calling 
for transparency of pharmaceutical 
research-and-development costs, 
adequate public return on public 
investment, and testing of new 
business models.5
This report comes at a time 
when the public appetite for 
change is growing, the pharma-
ceutical industry’s reputation is 
in the doldrums, and demand for 
a more equitable global trade sys-
tem is building. It puts forth ideas 
that deserve a fair hearing in coun-
tries struggling to provide access 
to medicines for their people and 
in the boardrooms of companies 
with the vision to try new ways 
of delivering innovation. Business 
as usual is no longer an option.
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Medicare is steadily shifting from volume-based fee-for-
service payments to value-based 
payment models, including ac-
countable care organizations, epi-
sode-based bundled payments, 
and penalties for hospitals with 
relatively high Medicare readmis-
sion rates.1 These models typically 
provide financial bonuses or pen-
alties related to the efficiency and 
quality of care, thereby shifting 
more financial risk to hospitals, 
medical groups, and other provid-
ers. Through a star rating system, 
bonuses are also provided to high-
quality health plans in the Medi-
care Advantage program.
A growing body of research in-
dicates that social risk factors, in-
cluding low socioeconomic posi-
tion (as indicated, for example, by 
income or educational level), mi-
nority race or ethnic background, 
lower degree of acculturation, mi-
nority sexual orientation or gender 
identity, limited social relation-
ships, and living alone or in a de-
prived neighborhood influence 
health outcomes.2 These findings 
are a concern for health care pro-
viders and policymakers because 
Medicare beneficiaries with such 
social risk factors are often con-
centrated among a subset of pro-
viders, particularly in inner-city or 
rural communities, and in some 
Medicare Advantage plans.
Without accounting for such 
risk factors, Medicare quality re-
porting and payment programs 
that financially reward or penalize 
health care providers according to 
the health outcomes of their pa-
tients will understate the quality of 
care provided by clinicians and or-
ganizations that disproportionately 
serve these populations and give 
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